Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Current Assets (2016 - 2025)

Iovance Biotherapeutics has reported Current Assets over the past 13 years, most recently at $442.7 million for Q4 2025.

  • Quarterly results put Current Assets at $442.7 million for Q4 2025, down 3.14% from a year ago — trailing twelve months through Dec 2025 was $442.7 million (down 3.14% YoY), and the annual figure for FY2025 was $442.7 million, down 3.14%.
  • Current Assets for Q4 2025 was $442.7 million at Iovance Biotherapeutics, up from $429.1 million in the prior quarter.
  • Over the last five years, Current Assets for IOVA hit a ceiling of $637.8 million in Q1 2023 and a floor of $274.9 million in Q2 2023.
  • Median Current Assets over the past 3 years was $425.8 million (2025), compared with a mean of $425.3 million.
  • Peak annual rise in Current Assets hit 48.46% in 2024, while the deepest fall reached 39.55% in 2024.
  • Iovance Biotherapeutics' Current Assets stood at $307.8 million in 2023, then skyrocketed by 48.46% to $457.0 million in 2024, then decreased by 3.14% to $442.7 million in 2025.
  • The last three reported values for Current Assets were $442.7 million (Q4 2025), $429.1 million (Q3 2025), and $422.5 million (Q2 2025) per Business Quant data.